Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Levin

Showing results (191-200 of 217) with videos related to

Pageof 22
Sort By:
Leukemia & Lymphoma|March 17, 2026
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemiaFlorian Simon, Rudy Ligtvoet, Moritz Fürstenau, et al.
Blood|August 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.
Blood Advances|August 22, 2025
Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trialFebe Smits, Kaz Groen, Mark-David Levin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 StudyClaudia A M Stege, Kazem Nasserinejad, Ellen van der Spek, et al.
Haematologica|November 27, 2014
Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patientsJaap J Zwaginga, Bronno van der Holt, Peter A Te Boekhorst, et al.
The New England Journal of Medicine|December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple MyelomaMeletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Eclinicalmedicine|September 8, 2023
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialKaz Groen, Claudia A M Stege, Kazem Nasserinejad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, et al.
Haematologica|September 22, 2018
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTORAndrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.
Blood|January 24, 2016
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myelomaSonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, et al.
Pageof 22

Showing results (191-200 of 217) with videos related to

Sort By:
Pageof 22
Leukemia & Lymphoma|March 17, 2026
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemiaFlorian Simon, Rudy Ligtvoet, Moritz Fürstenau, et al.
Blood|August 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.
Blood Advances|August 22, 2025
Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trialFebe Smits, Kaz Groen, Mark-David Levin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 StudyClaudia A M Stege, Kazem Nasserinejad, Ellen van der Spek, et al.
Haematologica|November 27, 2014
Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patientsJaap J Zwaginga, Bronno van der Holt, Peter A Te Boekhorst, et al.
The New England Journal of Medicine|December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple MyelomaMeletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Eclinicalmedicine|September 8, 2023
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialKaz Groen, Claudia A M Stege, Kazem Nasserinejad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, et al.
Haematologica|September 22, 2018
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTORAndrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.
Blood|January 24, 2016
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myelomaSonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, et al.
Pageof 22